CNS tumors, leukemia/lymphoma, and soft tissue sarcomas represent most malignancies in children. Over the past several decades, increased survival for childhood cancer has become a reality, owing to the improvements of multimodal treatments. Survival rates have increased, and many children are becoming long-term survivors of cancer. However, both cancers and their oncological treatment can lead to neurologic symptoms which cause deterioration of children’s quality of life. Neurological symptoms may be due to either mass effects by primary or secondary brain or spinal cord tumor mass, or paraneoplastic syndromes. Neurotoxicity secondary to cancer therapy are wide-range and heterogeneous. Common pediatric cancer treatments including surgery, chemotherapy, radiation therapy, bone marrow transplantation or immunotherapy can affect neurological functions through various pathomechanisms. Developing CNS is particularly susceptible to irradiation. The onset of these neurological sequelae can be acute, chronic, progressive or latent. Their severity varies from mild, transient symptoms to potentially a severe disabling, life-threatening or fatal illness, such as CNS infection, encephalopathy, cranial or peripheral neuropathy, vasculopathy, neurocognitive dysfunction, second malignancy etc...
Studies are needed to integrate emerging information on patient susceptibility and treatment with clinical risk factors for neurological complications. In this Research Topic, we try to identify novel interventions mitigating neurological complications among children undergoing cancer treatment. Multidisciplinary collaboration between primary care providers, pediatric oncologists, radiation oncologists and neuro-specialists is integral to the successful implementation of these interventions.
For this Research Topic, we would like to include Original Research and Review articles that focus on the pathophysiology, diagnosis, treatment, and outcomes of acute and long-term neurotoxicity in children treated for cancer. Topics will include both basic science and clinical research with a strong focus on, but not limited to, the following:
1. Emerging strategies in clinical management and prevention of neurological complications of cancer treatment
2. Impact of neurological complications on children with cancer.
3. Pathophysiology of neurological complications including paraneoplastic syndrome, encephalopathy, neuropathy, vasculopathy, neuro-endocrine dysfunction, and neurocognitive sequelae.
4. CNS infection management
5. Novel diagnostic approach and neuroimaging findings of neurological complications
6. Clinical trials targeting neuro-toxicity due to cancer therapy
Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
CNS tumors, leukemia/lymphoma, and soft tissue sarcomas represent most malignancies in children. Over the past several decades, increased survival for childhood cancer has become a reality, owing to the improvements of multimodal treatments. Survival rates have increased, and many children are becoming long-term survivors of cancer. However, both cancers and their oncological treatment can lead to neurologic symptoms which cause deterioration of children’s quality of life. Neurological symptoms may be due to either mass effects by primary or secondary brain or spinal cord tumor mass, or paraneoplastic syndromes. Neurotoxicity secondary to cancer therapy are wide-range and heterogeneous. Common pediatric cancer treatments including surgery, chemotherapy, radiation therapy, bone marrow transplantation or immunotherapy can affect neurological functions through various pathomechanisms. Developing CNS is particularly susceptible to irradiation. The onset of these neurological sequelae can be acute, chronic, progressive or latent. Their severity varies from mild, transient symptoms to potentially a severe disabling, life-threatening or fatal illness, such as CNS infection, encephalopathy, cranial or peripheral neuropathy, vasculopathy, neurocognitive dysfunction, second malignancy etc...
Studies are needed to integrate emerging information on patient susceptibility and treatment with clinical risk factors for neurological complications. In this Research Topic, we try to identify novel interventions mitigating neurological complications among children undergoing cancer treatment. Multidisciplinary collaboration between primary care providers, pediatric oncologists, radiation oncologists and neuro-specialists is integral to the successful implementation of these interventions.
For this Research Topic, we would like to include Original Research and Review articles that focus on the pathophysiology, diagnosis, treatment, and outcomes of acute and long-term neurotoxicity in children treated for cancer. Topics will include both basic science and clinical research with a strong focus on, but not limited to, the following:
1. Emerging strategies in clinical management and prevention of neurological complications of cancer treatment
2. Impact of neurological complications on children with cancer.
3. Pathophysiology of neurological complications including paraneoplastic syndrome, encephalopathy, neuropathy, vasculopathy, neuro-endocrine dysfunction, and neurocognitive sequelae.
4. CNS infection management
5. Novel diagnostic approach and neuroimaging findings of neurological complications
6. Clinical trials targeting neuro-toxicity due to cancer therapy
Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
